{"id":"NCT00888355","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension","officialTitle":"A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Losartan Given Once or Twice Daily in Patients With Mild to Moderate Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1992-05","primaryCompletion":"1993-01","completion":"1993-02","firstPosted":"2009-04-27","resultsPosted":"2009-06-24","lastUpdate":"2009-07-09"},"enrollment":428,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"losartan potassium","otherNames":["MK0954"]},{"type":"DRUG","name":"Comparator: placebo","otherNames":[]}],"arms":[{"label":"1","type":"PLACEBO_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"},{"label":"4","type":"EXPERIMENTAL"}],"summary":"The study had a 4 week single blind placebo period followed by 12 weeks of double blind treatment. Patients were randomized to one of four treatment arms to evaluate the antihypertensive efficacy of Losartan.","primaryOutcome":{"measure":"Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12","timeFrame":"At baseline, and at 12 weeks (24 hours after last morning dose and 12 hours after last PM dose)","effectByArm":[{"arm":"Placebo","deltaMin":-2,"sd":8.4},{"arm":"Losartan 25 mg q.d.","deltaMin":-5.8,"sd":6.7},{"arm":"Losartan 50 mg q.d.","deltaMin":-6.3,"sd":7.4},{"arm":"Losartan 25 mg (b.i.d.)","deltaMin":-8,"sd":7.9}],"pValues":[]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":11},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}